Dechra to use facility borrowings to finance Osurnia acquisitions

By Sarah Lizee

Olympia, Wash., Jan. 6 – Dechra Pharmaceuticals plc plans to use facility borrowings and existing cash to finance its acquisition of the Osurnia product portfolio from Elanco Animal Health Inc. for a total consideration of $135 million, according to a press release.

Closing is expected before the end of June 2020 following the satisfaction of some conditions.

Dechra said its acquisition of Osurnia is related to Elanco's acquisition of Bayer AG's animal health business, which is subject to regulatory approval from the European Commission and the Federal Trade Commission.

Dechra's acquisition of Osurnia is conditional upon approval of Dechra as a suitable buyer by the European Commission and the Federal Trade Commission in that context.

Dechra is a veterinary pharmaceuticals and related products business based in Northwich, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.